Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with Extension

This research study is investigating a new medicine, Losmapimod, for individuals diagnosed with Facioscapulohumeral Muscular Dystrophy 1, often called FSHD1. It's an early-stage study, meaning it's one of the first times this specific medicine is being tested in people with FSHD1. The main goals are to carefully check if the medicine is safe and if people can take it without too many side effects. Researchers will also look for any changes in markers in the body and how people's symptoms are affected. This type of study helps us understand if a new treatment might be helpful for FSHD1 in the future, laying the groundwork for larger studies.

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Fulcrum Therapeutics Inc.

Enrolment target

Start

11 Jun 2024

Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

What is this study about?

This study is a research project focusing on a condition called Facioscapulohumeral Muscular Dystrophy 1, or FSHD1. FSHD1 is a genetic condition that causes muscles to become weak, especially in the face, shoulders, and upper arms. There isn't a cure for FSHD1 yet, so scientists are always looking for new ways to manage the condition and improve the lives of people who have it.

In this study, researchers are testing a new medicine called Losmapimod. This is an "open-label" study, meaning both the patients and the doctors will know who is receiving the study medicine. It's also a "pilot study," which means it's a small, early-stage trial. The main purpose of this pilot study is to see if Losmapimod is safe for people with FSHD1 and how well their bodies tolerate it. They will closely watch for any side effects and how patients feel while taking the medicine.

Beyond safety, the study will also explore if Losmapimod makes any subtle changes in the body that can be measured (these are called biomarkers) and if it has any effect on how FSHD1 symptoms show up or progress. This initial information is really important because it helps doctors decide if Losmapimod should be studied in more detail in larger, longer trials in the future. It's a crucial step in the journey to finding new treatments.

Key takeaways

This study is exploring a new medicine (Losmapimod) for FSHD1.
It's an early-stage study focused on safety and tolerability.
Participants must be 18 years or older, both men and women are welcome.
Regular clinic visits for health checks and blood tests will be required.
There's no guarantee the medicine will help, and side effects are possible.
Joining is voluntary, and you can withdraw at any time.

Who may be eligible?

To join this study, you need to be an adult, at least 18 years old. There isn't an upper age limit mentioned, so adults of any age might be considered.

The study is open to both men and women. The detailed rules about who can and cannot take part will be explained by the study team, but generally, they will look for people with a confirmed diagnosis of Facioscapulohumeral Muscular Dystrophy 1 (FSHD1).

Other things like your general health, any other medications you are taking, or any other medical conditions you have will also be carefully checked to make sure it's safe for you to participate in this specific study. It’s important that you discuss all your health information openly with the study doctors.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)?
Are you able to attend regular clinic appointments?
Are you willing to take a new experimental medicine?
Are you comfortable with blood tests and other medical checks?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would be taking a medicine called Losmapimod. The study doctors would give you clear instructions on how and when to take it. Throughout the study, you would need to attend several appointments at the study clinic. During these visits, the doctors and nurses would check on your health and gather information.

These checks would include things like taking blood and urine samples (for laboratory tests), performing electrocardiograms (ECGs, which check your heart's electrical activity), and measuring your vital signs like blood pressure and heart rate. They would also ask you questions about how you are feeling and any side effects you might be experiencing. The total length of your participation, including any follow-up visits after you stop taking the medicine, would be fully explained by the study team.

Potential risks and benefits

Taking part in any medical study has both potential benefits and potential risks. You might benefit from closer medical attention and access to a new experimental medicine for FSHD1 that isn't widely available. While the specific benefits of Losmapimod for FSHD1 are still being investigated, this study could help advance knowledge that contributes to future treatments. However, there's always a risk that the medicine might not help your condition, or you might experience side effects. The study team will explain all the known and potential side effects. Remember, participating is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)?

FSHD1 is a genetic condition that causes muscles to become weak, especially in the face, shoulders, and upper arms.

What is the new medicine being tested?

The medicine being tested is called Losmapimod.

What is a 'pilot study'?

A pilot study is a small, early-stage trial designed mainly to check if a new medicine is safe and well-tolerated in people.

Will I know if I'm getting the study medicine?

Yes, this is an 'open-label' study, meaning everyone involved, including participants, will know you are receiving Losmapimod.

Can I leave the study once I've joined?

Yes, you can choose to leave the study at any time, for any reason, without it affecting your normal medical care.